Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
Iwanami, S.; Ejima, K.; Kim, K. S.; Noshita, K.; Fujita, Y.; Miyazaki, T.; Kohno, S.; Miyazaki, Y.; Morimoto, S.; Nakaoka, S.; Koizumi, Y.; Asai, Y.; Aihara, K.; Watashi, K.; Thompson, R. N.; Shibuya, K.; Fujiu, K.; Perelson, A. S.; Shingo, I.; Wakita, T.
Show abstract
Development of an effective antiviral drug for COVID-19 is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence for effective drugs from clinical studies is limited. The lack of evidence could be in part due to heterogeneity of virus dynamics among patients and late initiation of treatment. We first quantified the heterogeneity of viral dynamics which could be a confounder in compassionate use programs. Second, we demonstrated that an antiviral drug is unlikely to be effective if initiated after a short period following symptom onset. For accurate evaluation of the efficacy of an antiviral drug for COVID-19, antiviral treatment should be initiated before or soon after symptom onset in randomized clinical trials. One Sentence SummaryStudy design to evaluate antiviral effect.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial 93%
- Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study 93%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 93%
Similar papers in this journal
- Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 94%
- Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial 93%
- Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China 93%
Similar papers in this journal
- A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19) 92%
- Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection 92%
- Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis 91%
Similar papers in this journal
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 94%
- Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ) 93%
- A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis 92%
Similar papers in this journal
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial 94%
- Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study 93%
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.